Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ornithine phenylacetate - Yaqrit

Next Previous
Drug Profile

Ornithine phenylacetate - Yaqrit

Alternative Names: IV L-ornithine phenylacetate; L-Ornithine phenylacetate; MNK 6106; MNK-6105; OCR-002; OP; oral L-ornithine phenylacetate; Ornithine hydrochloride/sodium phenylacetate; Sodium phenylacetate/ornithine hydrochloride; UCL-L1V; YAQ006; YAQ007

Latest Information Update: 23 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University College London
  • Developer Ocera Therapeutics
  • Class Basic amino acids; Diamino amino acids; Esters; Hepatoprotectants; Neuroprotectants; Phenylacetates; Small molecules
  • Mechanism of Action Aminohydrolase modulators; Ammonia scavengers; NF-kappa B modulators; Nitric oxide synthase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure; Hepatic encephalopathy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Hepatic encephalopathy
  • Phase II Liver cirrhosis; Liver failure
  • No development reported Non-alcoholic fatty liver disease

Most Recent Events

  • 07 May 2025 Adverse events and pharmacodynamics data from a phase-IIa trial in Liver cirrhosis presented at the European Association for the Study of the Liver Congress 2025 (EASL-2025)
  • 07 May 2025 Yaqrit plans a phase IIb/III trial for Hepatic encephalopathy (Prevention) (PO)
  • 11 Feb 2025 Yaqrit plans a phase III trial for Hepatic-encephalopathy (IV) in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top